(Q33336635)
Statements
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer (English)
G Scarfone
G Giardina
A Villa
M Melpignano
M Presti
S Tateo
Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group